Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Zealand Pharma Articles

US FDA accepts Sanofi's NDA for diabetes drug lixisenatide

19 February 2013

Zealand Pharma valuation hinged on Lyxi/Lanti "fixflex"

23 November 2012

Sanofi files for Japanese approval of diabetes drug Lyxumia

11 June 2012

Abbott Labs acquires drug candidate from Action Pharma

4 May 2012

$20 million lixisenatide milestone for Zealand Pharma

13 February 2012

Sanofi files for EU approval of Lyxumia, a type-2 diabetes agent partnered with Zealand Pharma

4 November 2011

Sanofi presents positive results with Lyxumia and Lantus in type 2 diabetes at EASD meeting

13 September 2011

Boehringer gains global rights to Zealand’s diabetes/obesity compounds in 376 million-euro deal

17 June 2011

Positive Ph III results from Sanofi GetGoal Program on Lyxumia

1 June 2011

Sanofi-Aventis/Zealand’s diabetes drug lixisenatide equal to Lilly’s Byetta

3 February 2011

Zealand Pharma gets milestone from Helsinn on ZP1846 progress

10 December 2010

Positive new data on diabetes drugs from Novo Nordisk, AstraZeneca/B-MS and Sanofi-Aventis presented at EASD meeting

21 September 2010

Sanofi-Aventis in licensing deal with Vivalis for MAb targeting infectious diseases and extends accord with Zealand for diabetes product

8 June 2010

Showing 1-13 of 13 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Elan makes "transformational" acquisitions and a divestment
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Elan makes "transformational" acquisitions and a divestment

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS